Montelukast is an active ingredient widely used in the treatment of asthma and allergic rhinitis; it has been on the market for over twenty years and is available in numerous generic formulations.
The following article examines it from both therapeutic and manufacturing and distribution perspectives, exploring its mechanism of action and clinical uses.
Mechanism of action and uses
Montelukast belongs to the class of leukotriene receptor antagonists, substances involved in inflammatory processes in the airways. It works by blocking CysLT1 receptors, thereby helping to reduce bronchoconstriction, inflammation, and allergic symptoms. This active ingredient is mainly used in the treatment of:
- Persistent asthma: it helps to control respiratory symptoms and bronchial inflammation. It is mostly used as additional therapy in patients not adequately controlled with inhaled corticosteroids.
- Seasonal allergic rhinitis: during allergic reactions, it can help relieve symptoms such as nasal congestion, runny nose, and sneezing, particularly in patients with both asthma and allergic rhinitis.
- Exercise-induced bronchoconstriction: it can help prevent temporary narrowing of the airways, coughing, wheezing, and breathing difficulties during physical activity.
Marketed primarily as the sodium salt, it is available in various formulations, including coated or chewable tablets and oral granules for pediatric use.
Chemical and pharmaceutical properties
From an industrial perspective, montelukast remains an active ingredient of interest to pharmaceutical manufacturers, formulators, and distributors. From a chemical and pharmaceutical standpoint, the molecule exhibits certain characteristics that warrant particular attention during production.
Montelukast is sensitive to factors such as oxidation, light, and moisture, elements that can affect its stability and quality over time. The solid state of the API is also a significant consideration: parameters such as polymorphism, particle size, and crystal form can influence formulation properties, including dissolution and bioavailability, with a direct impact on the development of the finished product.
These aspects make it particularly important to control production and formulation conditions, in line with the standards set out in international pharmacopeias and applicable ICH guidelines.
Supply chain management and quality control
As is the case with many established active pharmaceutical ingredients available in various markets, the production and distribution of montelukast also involve complex global supply chains.
Combined with the molecule’s intrinsic characteristics, this underscores the importance of aspects such as quality control, material traceability, supply continuity, document reliability, and GMP compliance.
Supplier qualification and regulatory compliance management, therefore, play an increasingly vital role in ensuring quality and continuity throughout the supply chain. For this reason, Flarer supports its pharmaceutical partners in supplier qualification, auditing, regulatory support, and document management, GDP-compliant transport, and the management of import licenses – both in regulatory and customs contexts – helping to strengthen the reliability and control of the entire production and distribution chain. For further information, please get in touch with our team.